[go: up one dir, main page]

WO2008079406A3 - Marqueurs d'expression génique pour une maladie intestinale inflammatoire - Google Patents

Marqueurs d'expression génique pour une maladie intestinale inflammatoire Download PDF

Info

Publication number
WO2008079406A3
WO2008079406A3 PCT/US2007/026338 US2007026338W WO2008079406A3 WO 2008079406 A3 WO2008079406 A3 WO 2008079406A3 US 2007026338 W US2007026338 W US 2007026338W WO 2008079406 A3 WO2008079406 A3 WO 2008079406A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
bowel disease
gene expression
expression markers
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/026338
Other languages
English (en)
Other versions
WO2008079406A2 (fr
Inventor
Alexander Abbas
Hilary Clark
Lauri Diehl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of WO2008079406A2 publication Critical patent/WO2008079406A2/fr
Publication of WO2008079406A3 publication Critical patent/WO2008079406A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur des procédés de profilage d'expression génique pour une pathogenèse de maladie intestinale inflammatoire (IBD), dans lesquels l'expression différentielle dans un échantillon de test provenant d'un sujet mammifère d'un ou plusieurs marqueurs d'IBD par rapport à un témoin est déterminée, l'expression différentielle dans l'échantillon de test indiquant une IBD chez le sujet mammifère d'où provient l'échantillon de test.
PCT/US2007/026338 2006-12-19 2007-12-19 Marqueurs d'expression génique pour une maladie intestinale inflammatoire Ceased WO2008079406A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87081106P 2006-12-19 2006-12-19
US60/870,811 2006-12-19
US503607P 2007-11-29 2007-11-29
US61/005,036 2007-11-29

Publications (2)

Publication Number Publication Date
WO2008079406A2 WO2008079406A2 (fr) 2008-07-03
WO2008079406A3 true WO2008079406A3 (fr) 2008-12-31

Family

ID=39563123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/026338 Ceased WO2008079406A2 (fr) 2006-12-19 2007-12-19 Marqueurs d'expression génique pour une maladie intestinale inflammatoire

Country Status (1)

Country Link
WO (1) WO2008079406A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010067308A2 (fr) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides et polynucléotides, et utilisations de ceux-ci en tant que médicament cible pour produire des médicaments et des agents biologiques
AU2010276392A1 (en) * 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
MX347734B (es) 2010-06-14 2017-05-11 Lykera Biomed Sa Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2014139182A1 (fr) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions et méthodes d'utilisation de peptides de néogenèse d'îlots et d'analogues de ceux-ci

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006941A1 (fr) * 2002-07-17 2004-01-22 Index Pharmaceuticals Ab Composes antisens, methodes et compositions pour le traitement de troubles inflammatoires
WO2006063133A2 (fr) * 2004-12-06 2006-06-15 The Johns Hopkins University Biomarqueurs pour maladie intestinale inflammatoire
US20060263774A1 (en) * 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2006133287A2 (fr) * 2005-06-06 2006-12-14 Wyeth Profils d'expression des cellules mononucleaires du sang peripherique pour le traitement des maladies intestinales inflammatoires

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006941A1 (fr) * 2002-07-17 2004-01-22 Index Pharmaceuticals Ab Composes antisens, methodes et compositions pour le traitement de troubles inflammatoires
US20040132984A1 (en) * 2002-07-17 2004-07-08 Andreas Dieckmann Antisense compounds, methods and compositions for treating NGAL-related inflammatory disorders
US20060263774A1 (en) * 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2006063133A2 (fr) * 2004-12-06 2006-06-15 The Johns Hopkins University Biomarqueurs pour maladie intestinale inflammatoire
WO2006133287A2 (fr) * 2005-06-06 2006-12-14 Wyeth Profils d'expression des cellules mononucleaires du sang peripherique pour le traitement des maladies intestinales inflammatoires

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
19000101, 1 January 1900 (1900-01-01), XP008095674 *
CARLSON M ET AL: "Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, vol. 50, no. 4, 1 April 2002 (2002-04-01), pages 501 - 506, XP008097760, ISSN: 0017-5749 *
DOOLEY THOMAS P ET AL: "Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays.", INFLAMMATORY BOWEL DISEASES JAN 2004, vol. 10, no. 1, January 2004 (2004-01-01), pages 1 - 14, XP002501365, ISSN: 1078-0998 *
FUNAKOSHI K ET AL: "SPECTRUM OF CYTOKINE GENE EXPRESSION IN INTESTINAL MUCOSAL LESIONS OF CROHN'S DISEASE AND ULCERATIVE COLITIS", DIGESTION, BASEL, vol. 59, no. 1, 1 January 1998 (1998-01-01), pages 73 - 78, XP001064174, ISSN: 0012-2823 *
LAWRANCE I C ET AL: "Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes.", HUMAN MOLECULAR GENETICS 1 MAR 2001, vol. 10, no. 5, 1 March 2001 (2001-03-01), pages 445 - 456, XP002501364, ISSN: 0964-6906 *
LAWRANCE IAN C FIOCCHI C CHAKRAVARTI S: "Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, vol. 10, no. 5, 1 January 2001 (2001-01-01), pages 445 - 456, XP002955653, ISSN: 0964-6906 *
NIELSEN B S ET AL: "INDUCTION OF NGAL SYNTHESIS IN EPITHELIAL CELLS OF HUMAN COLORECTAL NEOPLASIA AND INFLAMMATORY BOWEL DISEASES", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, vol. 38, 1 January 1996 (1996-01-01), pages 414 - 420, XP002909706, ISSN: 0017-5749 *
NIELSEN O H ET AL: "Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis.", THE AMERICAN JOURNAL OF GASTROENTEROLOGY OCT 1999, vol. 94, no. 10, October 1999 (1999-10-01), pages 2923 - 2928, XP002501366, ISSN: 0002-9270 *
ROBERT BERKOW, ANDREW J. FLETCHER: "Merck Manual of Diagnosis and Therapy", 1992, MERCK RESEARCH LABORATORIES, RAHWAY, N.J. USA, XP002493450, 16 *
SANGFELT PER ET AL: "Local release of human neutrophil lipocalin (HNL), IL-8, and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis.", DIGESTIVE DISEASES AND SCIENCES SEP 2002, vol. 47, no. 9, September 2002 (2002-09-01), pages 2064 - 2069, XP002501367, ISSN: 0163-2116 *

Also Published As

Publication number Publication date
WO2008079406A2 (fr) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2009073565A3 (fr) Marqueur d'expression génique de maladie intestinale inflammatoire
EP2757160A3 (fr) Marqueurs d'expression génétique pour la maladie de Crohn
EP2021794B8 (fr) Utilisation de la protéine s100a 12 en tant que marqueur du cancer du côlon et du rectum
WO2008103962A3 (fr) Méthode de détection d'une maladie intestinale inflammatoire
WO2010088288A3 (fr) Détermination de différences du nombre de copies par amplification
EP2262911A4 (fr) Compositions, procédé et trousses utilisant des sondes synthétiques pour déterminer la présence d'un acide nucléique voulu
WO2010019414A3 (fr) Détection d'acide nucléique
WO2008085615A3 (fr) Procédés pour la détection d'un acide nucléique cible en formant une structure de clivage avec une sonde résistante au clivage
WO2011100541A3 (fr) Compositions et procédés de détection de petits arn
SI2089343T1 (sl) Klik kemija za proizvodnjo poročevalskih molekul
WO2012096545A3 (fr) Nouveau biomarqueur du cancer du pancréas utilisant les caractéristiques des cellules souches du cancer du pancréas, et son utilisation
WO2008054556A3 (fr) Procédés et compositions pour la détection d'une sequence d'acides nucléiques cible
WO2009086215A3 (fr) Analyse de voies de phénotypes de culture de cellules et utilisations de celle-ci
EP2075341A4 (fr) Procédé d'étude, de détermination ou d'évaluation par l'analyse de l'expression d'un gène
WO2008054514A3 (fr) Analyse différentielle de profils d'expression de phénotypes de cultures de cellules et utilisations de celle-ci
WO2008079406A3 (fr) Marqueurs d'expression génique pour une maladie intestinale inflammatoire
WO2008157299A3 (fr) Analyse de profil d'expression différentielle de phénotypes de culture cellulaire et ses utilisations
WO2007127493A3 (fr) Méthodes et réactifs servant à détecter la susceptibilité à la maladie du greffon contre l'hôte ou la mortalité liée à la greffe
WO2011100752A3 (fr) Procédés et matériaux pour l'évaluation de l'expression d'arn
WO2006063133A3 (fr) Biomarqueurs pour maladie intestinale inflammatoire
WO2006119326A3 (fr) Compositions de sondes/amorces oligonucleotidiques et procedes de detection de polynucleotides
WO2007130559A3 (fr) ProcÉdÉ de dÉtection de l'assÈchement d'une composition À base D'EAU utilisÉE dans un processus automatisÉ
WO2008090177A3 (fr) Diagnostic du cancer de la prostate
WO2009069001A3 (fr) Diagnostic utilisant la stratifine pour une maladie néoplasique
WO2010138963A3 (fr) Méthodes et systèmes servant à évaluer la sensibilité ou la résistance d'échantillons de tumeur à des agents chimiothérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07863246

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07863246

Country of ref document: EP

Kind code of ref document: A2